Aerovate Therapeutics, Inc.

NasdaqGM AVTE

Aerovate Therapeutics, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD -90.26 M

Aerovate Therapeutics, Inc. EBIT is USD -90.26 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -20.03% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Aerovate Therapeutics, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -75.19 M, a -64.71% change year over year.
Aerovate Therapeutics, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -45.65 M, a -139.48% change year over year.
Aerovate Therapeutics, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -19.06 M.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqGM: AVTE

Aerovate Therapeutics, Inc.

CEO	Mr. Timothy P. Noyes M.B.A.
IPO Date	June 30, 2021
Location	United States
Headquarters	930 Winter Street
Employees	51
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Key trends

Past 5 years